-
Sector Analysis
Prostate Cancer - Epidemiology Forecast to 2028
Prostate cancer is a malignancy in the prostate gland, which is located below the bladder and in front of the rectum in males. Worldwide, about 1.2 million men were diagnosed with prostate cancer in 2018 (International Agency for Research on Cancer, 2019). Almost all prostate cancers are adenocarcinomas, a type of cancer that develops in gland cells. Most prostate cancers are asymptomatic and grow very slowly. In advanced stages of prostate cancer, the malignancy has spread to other organs such...
-
Sector Analysis
Small Cell Lung Cancer - Diverse First-In-Class Pipeline Shows Promise of Targeted Therapies to Treat Aggressive Disease
Initially considered a curable disease due to substantial sensitivity to chemotherapy, small cell lung cancer (SCLC) remains a fatal disease with a poor outcome, with the majority of patients surviving one year or less after diagnosis. Unlike non-small cell lung cancer (NSCLC), in which major advances in treatment have been made following the approval of numerous targeted therapies, the field of SCLC has seen little advancement, and the standard of care (SOC) for several decades has been platinum-etoposide chemotherapy. Limited...
-
Sector Analysis
Ovarian Cancer - Epidemiology Forecast to 2028
Ovarian cancer is the most lethal gynecologic cancer and overall a leading cause of cancer incidence and mortality worldwide. The disease is defined as uncontrolled cell growth in the ovaries, although research has shown that the disease may actually originate in the fallopian tubes. GlobalData epidemiologists used age- and sex-specific diagnosed incidence rates to forecast the diagnosed incident cases, and used the observed survival rates to calculate the five-year diagnosed prevalent cases, taking into account the significant relationship between age...
-
Sector Analysis
Neuroendocrine Tumors - Epidemiology Forecast to 2030
The burden of diagnosed neuroendocrine tumors (NETs) is expected to increase at an annual growth rate (AGR) of 2.37% from an estimated 108,000 cases in 2020 to 133,000 in 2030 in the eight major markets (8MM*). This report reveals that the increase is attributed to the underlying demographic changes in the respective markets, and improvement in imaging tools used in diagnosis. In the 8MM, China accounts for approximately 36% of all diagnosed incident cases due to its large population. In the...
-
Product Insights
Glioma - Global Clinical Trials Review, H2, 2021
GlobalData's clinical trial report, “Glioma - Global Clinical Trials Review, H2, 2021" provides an overview of Glioma Clinical trials scenario. This report provides top line data relating to the clinical trials on Glioma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for...
-
Product Insights
Gliosarcoma - Global Clinical Trials Review, H2, 2021
GlobalData's clinical trial report, “Gliosarcoma - Global Clinical Trials Review, H2, 2021" provides an overview of Gliosarcoma Clinical trials scenario. This report provides top line data relating to the clinical trials on Gliosarcoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for...
-
Product Insights
Germ Cell Tumors - Global Clinical Trials Review, H2, 2021
GlobalData's clinical trial report, “Germ Cell Tumors - Global Clinical Trials Review, H2, 2021" provides an overview of Germ Cell Tumors Clinical trials scenario. This report provides top line data relating to the clinical trials on Germ Cell Tumors. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type....
-
Product Insights
Angiosarcoma - Global Clinical Trials Review, H2, 2021
GlobalData's clinical trial report, “Angiosarcoma - Global Clinical Trials Review, H2, 2021" provides an overview of Angiosarcoma Clinical trials scenario. This report provides top line data relating to the clinical trials on Angiosarcoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for...
-
Product Insights
Vaginal Cancer - Global Clinical Trials Review, H2, 2021
GlobalData's clinical trial report, “Vaginal Cancer - Global Clinical Trials Review, H2, 2021" provides an overview of Vaginal Cancer Clinical trials scenario. This report provides top line data relating to the clinical trials on Vaginal Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides...
-
Sector Analysis
Malignant Mesothelioma - Competitive Landscape in 2021
In malignant mesothelioma, cells expressing mesothelin is a major focus of drug developers. There are 178 drugs in the pipeline with 84% molecules present in early stage development. Big Pharma dominates R&D in this indication, with Bayer and Eli Lilly leading the way. The rise in treatment receiving population and increasing preference for branded tbiologic herapies will drive the market's growth over the next six years, but delayed diagnosis and low surveillance rate are likely to limit market growth.
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.